WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY • Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation (HSCT) is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of thiotepa [see Warnings and Precautions (5.1) ] • Thiotepa should be considered potentially carcinogenic in humans [see Warnings and Precautions (5.7)]<br>WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY See full prescribing information for complete boxed warning. • May cause severe marrow suppression or ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters [see Warnings and Precautions (5.1)] • Potentially carcinogenic in humans [see Warnings and Precautions (5.7)]<br>WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY • Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. Hematopoietic progenitor (stem) cell transplantation (HSCT) is required to prevent potentially fatal complications of the prolonged myelosuppression after high doses of thiotepa [see Warnings and Precautions (5.1) ] • Thiotepa should be considered potentially carcinogenic in humans [see Warnings and Precautions (5.7)] WARNING: SEVERE MYELOSUPPRESSION, CARCINOGENICITY See full prescribing information for complete boxed warning. • May cause severe marrow suppression or ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters [see Warnings and Precautions (5.1)] • Potentially carcinogenic in humans [see Warnings and Precautions (5.7)]